Comparison of Dosimetric Performance among Commercial Quality Assurance Systems for Verifying Pretreatment Plans of Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams
The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pr...
Saved in:
Published in | Journal of Korean medical science Vol. 31; no. 11; pp. 1742 - 1748 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
The Korean Academy of Medical Sciences
01.11.2016
대한의학회 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. |
---|---|
AbstractList | The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I’mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. KCI Citation Count: 0 The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I'mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I’mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam ® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan. |
Author | Song, Changhoon Kang, Sang-Won Suh, Tae Suk Choi, Kyoung-Sik Chung, Jin-Beom Eom, Keun-Yong |
AuthorAffiliation | 3 Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea 1 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea 4 Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea 2 Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea |
AuthorAffiliation_xml | – name: 1 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea – name: 4 Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea – name: 2 Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 3 Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Jin-Beom orcidid: 0000-0003-2668-3906 surname: Chung fullname: Chung, Jin-Beom organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 2 givenname: Sang-Won orcidid: 0000-0002-6376-7757 surname: Kang fullname: Kang, Sang-Won organization: Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 3 givenname: Keun-Yong orcidid: 0000-0003-3650-1133 surname: Eom fullname: Eom, Keun-Yong organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 4 givenname: Changhoon orcidid: 0000-0002-0714-8775 surname: Song fullname: Song, Changhoon organization: Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 5 givenname: Kyoung-Sik orcidid: 0000-0001-6247-4314 surname: Choi fullname: Choi, Kyoung-Sik organization: Department of Radiation Oncology, SAM Anyang Hospital, Anyang, Korea – sequence: 6 givenname: Tae Suk orcidid: 0000-0002-3057-1627 surname: Suh fullname: Suh, Tae Suk organization: Research Institute of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Biomedical Engineering, College of Medicine, The Catholic University of Korea, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27709851$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002164548$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9Ustu1DAUjVARfcAfIOQlLDLYie0kLJCmQwcqVWLog63lca5bd-J4sB2kfFj_D2emVMAC6Ur3Sj4P-_ocZwe96yHLXhM8K0vK399vbJgVmPBZSWYkVUWLZ9kRYU2d85JVB2nGhOR1U9LD7DiEe4wLxoryRXZYVBVuakaOsoeFs1vpTXA9chp9csFYiN4otAKvnbeyV4Ckdf0tSlALXhnZoW-D7Ewc0TyEwe8gV2OIYANKHPQdvNGjSZSVT2Igo4U-olUn-zC5XEXw4KJUMfmcunZEl7I1Lt6Bl9sR3YSJuuxkjNCnMV-aLjHypQdApyBteJk917IL8Oqxn2Q3y7PrxZf84uvn88X8IleUFjFnCnTNWqZ5yzHXlKqqrlkl1wAVp03ZEo31ek2hBI5lVcmmTitTnCtd0CKt6iR7t9ftvRYbZYSTZtdvndh4Mb-8PhekqGpOccJ-3GO3w9pCq9KLvezE1hsr_bhj_n3Sm7uk81MwzHiBWRJ4-yjg3Y8BQhTWBAVd2hq4IQhSl7RpaM0mrzd_ej2Z_P7XBKB7gPIuBA_6CUKwmOIjpviIKT6iJIKkSvFJtA__0JSJMho33dh0_yf_AldY0UY |
CitedBy_id | crossref_primary_10_1016_j_rpor_2019_07_007 crossref_primary_10_14316_pmp_2017_28_1_16 crossref_primary_10_1016_j_ejmp_2024_104822 crossref_primary_10_1088_2057_1976_ad2630 crossref_primary_10_1002_acm2_14352 crossref_primary_10_1016_j_radphyschem_2021_109739 crossref_primary_10_1016_j_ijrobp_2022_10_017 crossref_primary_10_1002_acm2_13645 crossref_primary_10_1007_s40846_018_0420_z |
Cites_doi | 10.1016/j.ejmp.2013.05.004 10.1088/0031-9155/55/8/003 10.1515/raon-2015-0021 10.3938/jkps.67.1672 10.1088/0031-9155/52/4/023 10.1120/jacmp.v11i4.3164 10.1186/1748-717X-6-113 10.1118/1.3533900 10.1118/1.2134929 10.1016/j.ijrobp.2010.10.002 10.1118/1.3685461 10.1120/jacmp.v13i4.3736 10.1120/jacmp.v12i2.3251 10.1016/j.radonc.2013.08.048 10.1120/jacmp.v14i6.4460 10.1016/j.zemedi.2010.07.003 10.1120/jacmp.v16i6.5728 10.1118/1.3431994 10.14316/pmp.2014.25.4.210 10.1016/j.ejmp.2015.05.016 10.1118/1.1591194 10.1186/1748-717X-5-110 10.3938/jkps.64.1207 10.1002/jmrs.78 |
ContentType | Journal Article |
Copyright | 2016 The Korean Academy of Medical Sciences. 2016 |
Copyright_xml | – notice: 2016 The Korean Academy of Medical Sciences. 2016 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3346/jkms.2016.31.11.1742 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1598-6357 |
EndPage | 1748 |
ExternalDocumentID | oai_kci_go_kr_ARTI_1278640 PMC5056205 27709851 10_3346_jkms_2016_31_11_1742 |
Genre | Journal Article Comparative Study |
GrantInformation_xml | – fundername: ; grantid: HI15C0638 – fundername: ; grantid: 2014R1A2A1A10050270 |
GroupedDBID | --- 29K 2WC 3O- 5-W 53G 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c442t-5cef85d5f6d606f44c78857abee76493d1f0fbb4e3e60a77a98101c66cf242523 |
IEDL.DBID | M48 |
ISSN | 1011-8934 1598-6357 |
IngestDate | Sun Mar 09 07:51:18 EDT 2025 Thu Aug 21 14:09:56 EDT 2025 Fri Jul 11 12:06:47 EDT 2025 Thu Apr 03 06:56:33 EDT 2025 Thu Apr 24 23:02:42 EDT 2025 Tue Jul 01 01:44:57 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Stereotactic Body Radiotherapy Delivery Quality Assurance Pretreatment Verification |
Language | English |
License | http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-5cef85d5f6d606f44c78857abee76493d1f0fbb4e3e60a77a98101c66cf242523 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Jin-Beom Chung and Sang-Won Kang contributed equally to this work. G704-000345.2016.31.11.007 |
ORCID | 0000-0001-6247-4314 0000-0003-3650-1133 0000-0002-0714-8775 0000-0002-6376-7757 0000-0002-3057-1627 0000-0003-2668-3906 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2016.31.11.1742 |
PMID | 27709851 |
PQID | 1834994850 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1278640 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5056205 proquest_miscellaneous_1834994850 pubmed_primary_27709851 crossref_primary_10_3346_jkms_2016_31_11_1742 crossref_citationtrail_10_3346_jkms_2016_31_11_1742 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-11-01 |
PublicationDateYYYYMMDD | 2016-11-01 |
PublicationDate_xml | – month: 11 year: 2016 text: 2016-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of Korean medical science |
PublicationTitleAlternate | J Korean Med Sci |
PublicationYear | 2016 |
Publisher | The Korean Academy of Medical Sciences 대한의학회 |
Publisher_xml | – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
References | Rinaldin (10.3346/jkms.2016.31.11.1742_ref26) 2014; 30 Kim (10.3346/jkms.2016.31.11.1742_ref5) 2011; 22 Chung (10.3346/jkms.2016.31.11.1742_ref13) 2015; 16 Iftimia (10.3346/jkms.2016.31.11.1742_ref23) 2010; 11 Son (10.3346/jkms.2016.31.11.1742_ref7) 2015; 49 Chandraraj (10.3346/jkms.2016.31.11.1742_ref31) 2011; 12 Kim (10.3346/jkms.2016.31.11.1742_ref4) 2014; 64 Cashmore (10.3346/jkms.2016.31.11.1742_ref11) 2011; 80 Kry (10.3346/jkms.2016.31.11.1742_ref9) 2010; 55 Lang (10.3346/jkms.2016.31.11.1742_ref16) 2012; 39 Nelms (10.3346/jkms.2016.31.11.1742_ref22) 2007; 8 Elith (10.3346/jkms.2016.31.11.1742_ref8) 2014; 61 Alvarez-Moret (10.3346/jkms.2016.31.11.1742_ref21) 2010; 5 Thomas (10.3346/jkms.2016.31.11.1742_ref2) 2005; 32 Ezzell (10.3346/jkms.2016.31.11.1742_ref3) 2003; 30 Masi (10.3346/jkms.2016.31.11.1742_ref27) 2011; 38 Scorsetti (10.3346/jkms.2016.31.11.1742_ref10) 2011; 6 Vieillevigne (10.3346/jkms.2016.31.11.1742_ref1) 2015; 31 Kim (10.3346/jkms.2016.31.11.1742_ref14) 2015; 67 Hussein (10.3346/jkms.2016.31.11.1742_ref29) 2013; 14 Chung (10.3346/jkms.2016.31.11.1742_ref15) 2014; 25 Jursinic (10.3346/jkms.2016.31.11.1742_ref20) 2010; 37 10.3346/jkms.2016.31.11.1742_ref17 Lee (10.3346/jkms.2016.31.11.1742_ref6) 2006; 17 10.3346/jkms.2016.31.11.1742_ref18 Shim (10.3346/jkms.2016.31.11.1742_ref25) 2012; 23 Hussein (10.3346/jkms.2016.31.11.1742_ref28) 2013; 109 Gloi (10.3346/jkms.2016.31.11.1742_ref19) 2011; 12 Kragl (10.3346/jkms.2016.31.11.1742_ref12) 2011; 21 Bailey (10.3346/jkms.2016.31.11.1742_ref24) 2012; 13 Herzen (10.3346/jkms.2016.31.11.1742_ref30) 2007; 52 22380368 - Med Phys. 2012 Mar;39(3):1351-6 20888199 - Z Med Phys. 2011 May;21(2):91-101 26401138 - Radiol Oncol. 2015 Aug 21;49(3):307-13 21587184 - J Appl Clin Med Phys. 2011 Apr 04;12(2):3367 20632595 - Med Phys. 2010 Jun;37(6):2837-46 21081873 - J Appl Clin Med Phys. 2010 Sep 01;11(4):3164 24100148 - Radiother Oncol. 2013 Dec;109(3):370-6 21587169 - J Appl Clin Med Phys. 2011 Jan 05;12 (2):3251 16475779 - Med Phys. 2005 Dec;32(12):3793-800 22766944 - J Appl Clin Med Phys. 2012 Jul 05;13(4):3736 26699585 - J Appl Clin Med Phys. 2015 Nov 08;16(6):5728 21167659 - Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1220-7 21092163 - Radiat Oncol. 2010 Nov 22;5:110 25598980 - J Med Radiat Sci. 2014 Dec;61(4):261-266 26095758 - Phys Med. 2015 Nov;31(7):720-5 23751395 - Phys Med. 2014 Mar;30(2):184-90 17264380 - Phys Med Biol. 2007 Feb 21;52(4):1197-208 20305334 - Phys Med Biol. 2010 Apr 21;55(8):2155-66 21452698 - Med Phys. 2011 Feb;38(2):612-21 17712302 - J Appl Clin Med Phys. 2007 Jul 17;8(3):2448 21910868 - Radiat Oncol. 2011 Sep 12;6:113 24257288 - J Appl Clin Med Phys. 2013 Nov 04;14(6):4460 12945975 - Med Phys. 2003 Aug;30(8):2089-115 |
References_xml | – volume: 30 start-page: 184 year: 2014 ident: 10.3346/jkms.2016.31.11.1742_ref26 publication-title: Phys Med doi: 10.1016/j.ejmp.2013.05.004 – volume: 55 start-page: 2155 year: 2010 ident: 10.3346/jkms.2016.31.11.1742_ref9 publication-title: Phys Med Biol doi: 10.1088/0031-9155/55/8/003 – volume: 49 start-page: 307 year: 2015 ident: 10.3346/jkms.2016.31.11.1742_ref7 publication-title: Radiol Oncol doi: 10.1515/raon-2015-0021 – volume: 67 start-page: 1672 year: 2015 ident: 10.3346/jkms.2016.31.11.1742_ref14 publication-title: J Korean Phys Soc doi: 10.3938/jkps.67.1672 – ident: 10.3346/jkms.2016.31.11.1742_ref18 – volume: 52 start-page: 1197 year: 2007 ident: 10.3346/jkms.2016.31.11.1742_ref30 publication-title: Phys Med Biol doi: 10.1088/0031-9155/52/4/023 – volume: 11 start-page: 3164 year: 2010 ident: 10.3346/jkms.2016.31.11.1742_ref23 publication-title: J Appl Clin Med Phys doi: 10.1120/jacmp.v11i4.3164 – volume: 23 start-page: 33 year: 2012 ident: 10.3346/jkms.2016.31.11.1742_ref25 publication-title: Korean J Med Phys – volume: 12 start-page: 3367 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref31 publication-title: J Appl Clin Med Phys – volume: 22 start-page: 61 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref5 publication-title: Korean J Med Phys – volume: 8 start-page: 2448 year: 2007 ident: 10.3346/jkms.2016.31.11.1742_ref22 publication-title: J Appl Clin Med Phys – volume: 6 start-page: 113 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref10 publication-title: Radiat Oncol doi: 10.1186/1748-717X-6-113 – volume: 38 start-page: 612 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref27 publication-title: Med Phys doi: 10.1118/1.3533900 – volume: 32 start-page: 3793 year: 2005 ident: 10.3346/jkms.2016.31.11.1742_ref2 publication-title: Med Phys doi: 10.1118/1.2134929 – volume: 80 start-page: 1220 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref11 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.10.002 – volume: 17 start-page: 131 year: 2006 ident: 10.3346/jkms.2016.31.11.1742_ref6 publication-title: Korean J Med Phys – volume: 39 start-page: 1351 year: 2012 ident: 10.3346/jkms.2016.31.11.1742_ref16 publication-title: Med Phys doi: 10.1118/1.3685461 – volume: 13 start-page: 3736 year: 2012 ident: 10.3346/jkms.2016.31.11.1742_ref24 publication-title: J Appl Clin Med Phys doi: 10.1120/jacmp.v13i4.3736 – volume: 12 start-page: 3251 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref19 publication-title: J Appl Clin Med Phys doi: 10.1120/jacmp.v12i2.3251 – volume: 109 start-page: 370 year: 2013 ident: 10.3346/jkms.2016.31.11.1742_ref28 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2013.08.048 – volume: 14 start-page: 4460 year: 2013 ident: 10.3346/jkms.2016.31.11.1742_ref29 publication-title: J Appl Clin Med Phys doi: 10.1120/jacmp.v14i6.4460 – volume: 21 start-page: 91 year: 2011 ident: 10.3346/jkms.2016.31.11.1742_ref12 publication-title: Z Med Phys doi: 10.1016/j.zemedi.2010.07.003 – ident: 10.3346/jkms.2016.31.11.1742_ref17 – volume: 16 start-page: 5728 year: 2015 ident: 10.3346/jkms.2016.31.11.1742_ref13 publication-title: J Appl Clin Med Phys doi: 10.1120/jacmp.v16i6.5728 – volume: 37 start-page: 2837 year: 2010 ident: 10.3346/jkms.2016.31.11.1742_ref20 publication-title: Med Phys doi: 10.1118/1.3431994 – volume: 25 start-page: 210 year: 2014 ident: 10.3346/jkms.2016.31.11.1742_ref15 publication-title: Prog Med Phys doi: 10.14316/pmp.2014.25.4.210 – volume: 31 start-page: 720 year: 2015 ident: 10.3346/jkms.2016.31.11.1742_ref1 publication-title: Phys Med doi: 10.1016/j.ejmp.2015.05.016 – volume: 30 start-page: 2089 year: 2003 ident: 10.3346/jkms.2016.31.11.1742_ref3 publication-title: Med Phys doi: 10.1118/1.1591194 – volume: 5 start-page: 110 year: 2010 ident: 10.3346/jkms.2016.31.11.1742_ref21 publication-title: Radiat Oncol doi: 10.1186/1748-717X-5-110 – volume: 64 start-page: 1207 year: 2014 ident: 10.3346/jkms.2016.31.11.1742_ref4 publication-title: J Korean Phys Soc doi: 10.3938/jkps.64.1207 – volume: 61 start-page: 261 year: 2014 ident: 10.3346/jkms.2016.31.11.1742_ref8 publication-title: J Med Radiat Sci doi: 10.1002/jmrs.78 – reference: 21587184 - J Appl Clin Med Phys. 2011 Apr 04;12(2):3367 – reference: 16475779 - Med Phys. 2005 Dec;32(12):3793-800 – reference: 17712302 - J Appl Clin Med Phys. 2007 Jul 17;8(3):2448 – reference: 22380368 - Med Phys. 2012 Mar;39(3):1351-6 – reference: 26401138 - Radiol Oncol. 2015 Aug 21;49(3):307-13 – reference: 20888199 - Z Med Phys. 2011 May;21(2):91-101 – reference: 21167659 - Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1220-7 – reference: 23751395 - Phys Med. 2014 Mar;30(2):184-90 – reference: 21452698 - Med Phys. 2011 Feb;38(2):612-21 – reference: 22766944 - J Appl Clin Med Phys. 2012 Jul 05;13(4):3736 – reference: 21092163 - Radiat Oncol. 2010 Nov 22;5:110 – reference: 21081873 - J Appl Clin Med Phys. 2010 Sep 01;11(4):3164 – reference: 24100148 - Radiother Oncol. 2013 Dec;109(3):370-6 – reference: 20632595 - Med Phys. 2010 Jun;37(6):2837-46 – reference: 26699585 - J Appl Clin Med Phys. 2015 Nov 08;16(6):5728 – reference: 24257288 - J Appl Clin Med Phys. 2013 Nov 04;14(6):4460 – reference: 21910868 - Radiat Oncol. 2011 Sep 12;6:113 – reference: 17264380 - Phys Med Biol. 2007 Feb 21;52(4):1197-208 – reference: 20305334 - Phys Med Biol. 2010 Apr 21;55(8):2155-66 – reference: 21587169 - J Appl Clin Med Phys. 2011 Jan 05;12 (2):3251 – reference: 25598980 - J Med Radiat Sci. 2014 Dec;61(4):261-266 – reference: 26095758 - Phys Med. 2015 Nov;31(7):720-5 – reference: 12945975 - Med Phys. 2003 Aug;30(8):2089-115 |
SSID | ssj0025523 |
Score | 2.1628025 |
Snippet | The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1742 |
SubjectTerms | Algorithms Bone Neoplasms - radiotherapy Humans Lung Neoplasms - radiotherapy Male Original Prostatic Neoplasms - radiotherapy Quality Assurance, Health Care Radiometry - instrumentation Radiometry - methods Radiosurgery Radiotherapy Dosage Retrospective Studies 의학일반 |
Title | Comparison of Dosimetric Performance among Commercial Quality Assurance Systems for Verifying Pretreatment Plans of Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27709851 https://www.proquest.com/docview/1834994850 https://pubmed.ncbi.nlm.nih.gov/PMC5056205 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002164548 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Korean Medical Science, 2016, 31(11), 221, pp.1742-1748 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELaWRUJcEG_KozKIq1ESv9IDQuxCtAsqWgFFe7MSx4aobQJpK9Efxv9jxkkDRbvilEPsWMmM7fkynu8j5LmDoHiiY8e85QkTEx6z1JaSuVLFTnvYYoJo3_SDOpmJd-fy_IDsNFv7D7i6ENqhntSsXbz4-WP7Cib8S0ScHDOU8yUSb8cKACgsAXhGBxblq7A3aZyqUzHkFSB-TnhXQHdpT6QH1jqapDLe26uu1K2_KAz99zTlX9tTdpPc6ONK-rpzhFvkwNW3ybVpnzm_Q34dD4KDtPH0TbOqliimZenZn9IBGqSHKBaNoBATPK-j2NhSsOKmDU16inMKfegXcN9QJ0XPWjccWacohLTCUT6B0VyzDnVY9Kgpt_RjXlZ9zdeWhuMKNFsgxSf-nmFZhbl7lrXO0SOXL1d3ySx7-_n4hPWSDcwKkayZtM6nspReleAEXggLEFvqvHBOK_CEMvaRLwrhODhJrnU-QYIxq5T1iH0Sfo8c1k3tHhCaF567yOnEFkrIPC18XFpbxErm3kaWjwjfGcfYns8cZTUWBnANWtegdQ1a1_AYkI5B644IG3p97_g8_tP-GdjdzG1lkIgbr18bM28NwI1TEyc6VSIakac7tzAwOzHlkteu2awMLJgAKUUqoc39zk2GYXdeNiJ6z4GGBjjg_p26-hYYwEPYGsmHlz7zEbmOL9IVTT4mh-t2455A9LQuxoAbTt-Pw7-HcZgcvwGlSh0g |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Dosimetric+Performance+among+Commercial+Quality+Assurance+Systems+for+Verifying+Pretreatment+Plans+of+Stereotactic+Body+Radiotherapy+Using+Flattening-Filter-Free+Beams&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Chung%2C+Jin+Beom&rft.au=Kang%2C+Sang+Won&rft.au=Eom%2C+Keun+Yong&rft.au=Song%2C+Changhoon&rft.date=2016-11-01&rft.eissn=1598-6357&rft.volume=31&rft.issue=11&rft.spage=1742&rft_id=info:doi/10.3346%2Fjkms.2016.31.11.1742&rft_id=info%3Apmid%2F27709851&rft.externalDocID=27709851 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |